UA85180U - Method for treating osteoarthrosis in adolescents - Google Patents

Method for treating osteoarthrosis in adolescents

Info

Publication number
UA85180U
UA85180U UAU201306523U UAU201306523U UA85180U UA 85180 U UA85180 U UA 85180U UA U201306523 U UAU201306523 U UA U201306523U UA U201306523 U UAU201306523 U UA U201306523U UA 85180 U UA85180 U UA 85180U
Authority
UA
Ukraine
Prior art keywords
year
osteoarthrosis
progression
teraflex
synovitis
Prior art date
Application number
UAU201306523U
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Наталья Станиславовна Шевченко
Ирина Степановна Лебец
Ольга Исаковна Гармаш
Original Assignee
Государственное Учреждение «Институт Охраны Здоровья Детей И Подростков Национальной Академии Медицинских Наук Украины»
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Государственное Учреждение «Институт Охраны Здоровья Детей И Подростков Национальной Академии Медицинских Наук Украины» filed Critical Государственное Учреждение «Институт Охраны Здоровья Детей И Подростков Национальной Академии Медицинских Наук Украины»
Priority to UAU201306523U priority Critical patent/UA85180U/en
Publication of UA85180U publication Critical patent/UA85180U/en

Links

Abstract

A method for treating osteoarthrosis in the adolescents provides for the use of medicinal products. In case of disease progression at the initial stages, the health resort treatment for rehabilitation is also provided. The following therapeutics are used: non-steroid anti-inflammatory agents for 2-3 weeks (Movalis or Diclofenac) followed by Zinaxin (3-4 months) with simultaneous course of Teraflex (for 2 months twice a year) – in osteoarthrosis with synovitis and risk or manifestation of progression; Teraflex for 2 months twice a year every year – in osteoarthrosis without synovitis but with risk or manifestation of progression; and chondroprotectors, for examples – Teraflex for 2 months twice a year for 2 years in succession or Alflutop 2-3 times a year for 2 years – in osteoarthrosis without synovitis and without risk or manifestation of progression.
UAU201306523U 2013-05-27 2013-05-27 Method for treating osteoarthrosis in adolescents UA85180U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU201306523U UA85180U (en) 2013-05-27 2013-05-27 Method for treating osteoarthrosis in adolescents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU201306523U UA85180U (en) 2013-05-27 2013-05-27 Method for treating osteoarthrosis in adolescents

Publications (1)

Publication Number Publication Date
UA85180U true UA85180U (en) 2013-11-11

Family

ID=52284647

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU201306523U UA85180U (en) 2013-05-27 2013-05-27 Method for treating osteoarthrosis in adolescents

Country Status (1)

Country Link
UA (1) UA85180U (en)

Similar Documents

Publication Publication Date Title
PH12017500933A1 (en) Sublingual administration of riluzole
EA201500934A1 (en) CARDIO AND NEPHROPROTECTIVE ANTI-DIABETIC THERAPY
EA201791199A1 (en) METHOD OF TREATMENT OF ALZHEIMER'S DISEASE
EA201691481A1 (en) C5a inhibitors for the treatment of viral pneumonia
PH12017500934A1 (en) Sublingual formulation of riluzole
SG10201809701TA (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
MY195038A (en) A Modified Release Composition of Orlistat and Acarbose for the Treatment of Obesity and Related Metabolic Disorders
EA201790726A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ULCERAL COLITIS
CY1121566T1 (en) NEUROPROTECTIVE AND INDICATION OF THIS
MX2021013354A (en) Methods of treating and/or preventing actinic keratosis.
EA201691918A1 (en) PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE
MX2021010886A (en) Medicaments for slowing parkinson's disease.
CY1119532T1 (en) (S) -PYRILDOL AND THE PHARMACEUTALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
EA201991175A1 (en) THE USE OF INTERFERON-LAMBDA IN MEDICINE FOR THE TREATMENT OF FIBROSIS
DK3383872T3 (en) 1,3,4-THIADIAZOLIC COMPOUNDS AND ITS USE IN CANCER TREATMENT
CY1119522T1 (en) (R) - PILINDOL AND THE PHARMACEUTICALALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
TR201905218T4 (en) USEFUL VITANOLIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES.
AR106313A1 (en) COMBINATION OF LEVODOPA DEUTERATED WITH CARBIDOPA AND OPICAPONE FOR PARKINSON'S DISEASE TREATMENT
MD4763B1 (en) Pharmaceutical composition
FR3045392B1 (en) DEVICE FOR THE TREATMENT OF A SUBJECT BY COMBINING IN PARTICULAR LITHOTHERAPY, CHROMOTHERAPY, LUMINOTHERAPY AND MUSIC THERAPY
TR201819662T4 (en) Orally dispersible film composition containing enalapril for the treatment of childhood hypertension.
PH12016502284A1 (en) Cough medicine containing ambroxol hydrochloride
UA85180U (en) Method for treating osteoarthrosis in adolescents
EA201790973A1 (en) A-ANTAGONIST IN LOW DOSAGE FOR ADHD TREATMENT AND PARKINSON'S DISEASE
RU2014154366A (en) APPLICATION OF THE PROBIOTIC STRAIN OF THE MICROOORGANISM ENTEROCOCCUS FAECIUM L3 FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES